Abbott's FreeStyle glucose monitor:
This article was originally published in Clinica
Abbott Diabetes Care has received US FDA 510(k) clearance to market its FreeStyle Connect blood glucose monitor in point-of-care (POC) settings in hospitals and medical clinics. The device, claims the Alameda, California-based division of Abbott, measures glucose levels using the smallest sample size (0.3 microlitres) required of any POC blood glucose monitoring product on the market. It is also the fastest POC glucose monitoring system available, providing results within an average of 15 seconds, the company added. Abbott added the FreeStyle product to its diabetes portfolio through its 2004 acquisition of Alameda, California-based TheraSense.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.